source
- Roche partners with Chinese biotech Defand Therapeutics to co-develop new medicinesRoche announced a partnership with Chinese biotech startup Defand Therapeutics aimed at joint discovery of new drug candidates. Unlike the typical licensing deals where companies obtain rights to…
- Argenx halts late-stage Vyvgart trial in Sjogren’s disease after futility finding, shares tumble 13%Argenx announced it is ending the Phase 3 UNITY trial of its Vyvgart Hytrulo injection in Sjogren’s disease after an independent data monitoring committee concluded the study would not meet its pri…